Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies.
Tobias SprengerVolker SchirrmacherWilfried StückerStefaan W van GoolPublished in: Expert review of anticancer therapy (2020)
Highly specialized translational oncology groups like the IOZK can contribute to medical progress and quick transfer 'from bench to bedside.' Their contribution should be acknowledged and taken into account more strongly in the development of guidelines and the reimbursement of therapy costs. Methodological plurality should be encouraged.